Education
About Us
Working with TipRanks
Follow Us
Cero Therapeutics Holdings, Inc. (CERO)
:CERO
Total Valuation
CERo Therapeutics Holdings has a market cap or net worth of $3.44M. The enterprise value is ―.
Market Cap$3.44M
Enterprise Value―
Share Statistics
CERo Therapeutics Holdings has 5,380,723 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,380,723
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CERo Therapeutics Holdings’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is -61.65%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-61.65%
Return on Capital Employed (ROCE)-0.87
Revenue Per Employee0.00
Profits Per Employee0.00
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CERo Therapeutics Holdings is -2.83M. CERo Therapeutics Holdings’s PEG ratio is -9.58K.
PE Ratio-2.83M
PS Ratio―
PB Ratio-505.72
Price to Fair Value-505.72
Price to FCF-4.73M
Price to Operating Cash Flow-4.71M
PEG Ratio-9.58K
Income Statement
In the last 12 months, CERo Therapeutics Holdings had revenue of 0.00 and earned ― in profits. Earnings per share was -0.39.
Revenue0.00
Gross Profit0.00
Operating Income-2.93M
Pretax Income-2.44M
Net Income―
EBITDA-2.44M
Earnings Per Share (EPS)-0.39
Cash Flow
In the last 12 months, operating cash flow was -10.12M and capital expenditures 4.00, giving a free cash flow of -10.12M billion.
Operating Cash Flow-10.12M
Free Cash Flow-10.12M
Free Cash Flow per Share-1.88
Dividends & Yields
CERo Therapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.25
52-Week Price Change-99.55%
50-Day Moving Average1.19
200-Day Moving Average8.97
Relative Strength Index (RSI)32.93
Average Volume (3m)881.00K
Important Dates
CERo Therapeutics Holdings upcoming earnings date is ―, TBA Not Confirmed.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
CERo Therapeutics Holdings as a current ratio of 1.65, with Debt / Equity ratio of -48.75%
Current Ratio1.65
Quick Ratio1.65
Debt to Market Cap<0.01
Net Debt to EBITDA-0.60
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CERo Therapeutics Holdings has paid 94.82K in taxes.
Income Tax94.82K
Effective Tax Rate-0.04
Enterprise Valuation
CERo Therapeutics Holdings EV to EBITDA ratio is -2.94K, with an EV/FCF ratio of -4.73M.
EV to Sales0.00
EV to EBITDA-2.94K
EV to Free Cash Flow-4.73M
EV to Operating Cash Flow-4.71M
Balance Sheet
CERo Therapeutics Holdings has $3.38M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$1.58M billion.
Cash & Marketable Securities$3.38M
Total Debt$0.00
Net Cash-$1.58M
Net Cash Per Share-$0.29
Tangible Book Value Per Share-$2.18
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CERo Therapeutics Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―